New study tracks ilaris safety in rare fever patients
NCT ID NCT06838143
First seen Jan 04, 2026 · Last updated May 01, 2026 · Updated 17 times
Summary
This study watches children and adults with certain rare fever diseases (like CAPS, FMF, TRAPS, HIDS/MKD, and sJIA) who are already taking or starting Ilaris. Researchers will track side effects and how well the drug controls fevers and flares. No new treatment is given — it just collects real-world data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGSeoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.